AR126708A1 - Vacuna para el vph - Google Patents
Vacuna para el vphInfo
- Publication number
- AR126708A1 AR126708A1 ARP220102097A ARP220102097A AR126708A1 AR 126708 A1 AR126708 A1 AR 126708A1 AR P220102097 A ARP220102097 A AR P220102097A AR P220102097 A ARP220102097 A AR P220102097A AR 126708 A1 AR126708 A1 AR 126708A1
- Authority
- AR
- Argentina
- Prior art keywords
- hpv
- vlps
- chitosan
- type
- composition
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 241000701806 Human papillomavirus Species 0.000 abstract 18
- 229920001661 Chitosan Polymers 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- 239000002245 particle Substances 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 229960002566 papillomavirus vaccine Drugs 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación proporciona, entre otras cosas, una composición de vacuna de dosis única que incluye un adyuvante de quitosano y partículas similivíricas del PVH (las VLP) de al menos un tipo del papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos del PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82, en que la composición de vacuna de dosis única proporciona una respuesta de vacuna para el PVH potenciada o comparable en comparación con una vacuna de dosis múltiples similar formulada sin tal adyuvante de quitosano. Reivindicación 1: Una composición farmacéutica que comprende: partículas similivíricas (las VLP) de al menos un tipo del papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos del PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 5 51, 52, 53, 55, 56, 58, 59, 66, 68, 69, 70, 73 y 82, un quitosano; y un transportador farmacéuticamente aceptable. Reivindicación 42: Una composición farmacéutica que comprende partículas similivíricas (las VLP) de al menos un tipo del papilomavirus humano (PVH), en donde el al menos un tipo del PVH se selecciona del grupo que consiste en los tipos del PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82; y 0,1 mg a aproximadamente 50 mg de un quitosano, en donde las VLP de PVH comprenden proteína Ll del PVH recombinante o proteína L1 + L2 del PVH recombinante, en donde las VLP de PVH de cada uno de los al menos uno de los tipos del PVH están presentes en una concentración de aproximadamente 10 mg a aproximadamente 300 mg por 0,5 ml de la composición farmacéutica, y en donde la concentración total de VLP está entre 10 mg y 2000 mg por 0,5 ml de la composición farmacéutica. Reivindicación 75: Una composición de vacuna de dosis única que comprende: un quitosano, partículas similivíricas (las VLP) de al menos un tipo del papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos del PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82, y un transportador farmacéuticamente aceptable; en donde la composición de vacuna de dosis única proporciona una respuesta inmunitaria anti-PVH elevada o comparable con respecto a dosis múltiples de la misma composición formulada sin un adyuvante de quitosano.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163230426P | 2021-08-06 | 2021-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR126708A1 true AR126708A1 (es) | 2023-11-08 |
Family
ID=83193593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220102097A AR126708A1 (es) | 2021-08-06 | 2022-08-04 | Vacuna para el vph |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230048144A1 (es) |
EP (1) | EP4380615A1 (es) |
AR (1) | AR126708A1 (es) |
TW (1) | TW202313658A (es) |
WO (1) | WO2023014853A1 (es) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
WO1996011272A2 (de) | 1994-10-07 | 1996-04-18 | Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
US5820870A (en) | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
EP1608767B1 (en) | 2003-03-24 | 2012-02-22 | Merck Sharp & Dohme Corp. | Optimized expression of hpv 31 l1 in yeast |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
CN1934131B (zh) | 2004-03-24 | 2010-12-29 | 默沙东公司 | Hpv52l1在酵母中的优化表达 |
EP1877086A2 (en) | 2005-04-26 | 2008-01-16 | GlaxoSmithKline Biologicals SA | Vaccine |
CN109464661B (zh) * | 2018-12-14 | 2022-05-10 | 中国科学院过程工程研究所 | 一种疫苗抗原组合物及其制备方法 |
-
2022
- 2022-08-04 AR ARP220102097A patent/AR126708A1/es unknown
- 2022-08-04 TW TW111129328A patent/TW202313658A/zh unknown
- 2022-08-04 EP EP22765291.4A patent/EP4380615A1/en active Pending
- 2022-08-04 US US17/817,382 patent/US20230048144A1/en active Pending
- 2022-08-04 WO PCT/US2022/039371 patent/WO2023014853A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023014853A1 (en) | 2023-02-09 |
EP4380615A1 (en) | 2024-06-12 |
US20230048144A1 (en) | 2023-02-16 |
TW202313658A (zh) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005521398A5 (es) | ||
JP7239910B2 (ja) | 治療剤、ならびに腫瘍および/またはがんの治療のための薬物のためのその使用 | |
US12059443B2 (en) | Method for treating cancer using dengue virus serotype 1 (DENV-1) | |
EP2950817B1 (en) | Immunogenic compositions comprising silicified virus and methods of use | |
CO2022011392A2 (es) | Vacuna contra hpv | |
CN108977412A (zh) | 用于提高病毒感染性的方法 | |
EP3638303A1 (en) | Compositions and methods for cancer therapy with dengue virus and dendritic cells | |
JP2016508999A5 (es) | ||
IL305911A (en) | Multifunctional nanoparticle vaccines for influenza | |
EP3316897A1 (en) | Compositions and methods for combination therapy with dengue virus and dendritic cells | |
ES2330540T3 (es) | Parapoxvirus en combinacion con otros agentes antivirales para el tratamiento de vih/sida. | |
Huang et al. | Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice | |
AR126708A1 (es) | Vacuna para el vph | |
Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
Fallah et al. | Features of pathobiology and clinical translation of approved treatments for Coronavirus Disease 2019 | |
AR097881A1 (es) | FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO | |
UY38933A (es) | Vacuna de partículas tipo virus del chicunguña y métodos para su uso | |
Leonova et al. | Effect of Glycosaminoglycans on Pathogenic Properties Far-Eastern Tick-Borne Encephalitis Virus | |
Nag et al. | COVID-19 vaccines: an account of need and efficacy vs safety and challenges | |
Pourjabbar et al. | Cell Therapy Based SARS-cov 2-2019 Managements: A Literature Review | |
AR120296A1 (es) | Vacuna de partículas de virus de tipo chikungunya y sus métodos de uso | |
Mukhim | African Swine Fever Virus: A Review on Its Heterogeneity, Immunomodulatory Property and Its Extent of Virulence | |
EP3244922A1 (en) | Methods of inducing an immune response to hepatitis c virus |